Sunshine Biopharma INC 8-K filings

Sunshine Biopharma obtained shareholder consent to modify terms of its Series A and B warrants, including adjustments to exercise prices and cashless exercise options.

Sunshine Biopharma has successfully priced a $10 million underwritten public offering to fund general corporate purposes and working capital.

Sunshine Biopharma has repurchased and cancelled outstanding warrants from 2022 and 2023 for a total of $3,139,651, eliminating potential future dilution.

Sunshine Biopharma has appointed a new Chief Operating Officer and Chief Development Officer, while other executives retain their positions.